冠心病患者血浆尾加压素Ⅱ血管紧张素Ⅱ和内皮素-1水平及临床意义  

Levels of plasma urotensin Ⅱ angiotensin Ⅱ and endothelin-1 in patients with coronary heart disease and their clinical significance

作　　者：王晓燕[1] 卢彬[2] 郭唤[2] 

机构地区：[1]济宁医学院卫生科,山东济宁272013 [2]济宁医学院附属医院,山东济宁272029

出　　处：《济宁医学院学报》2009年第3期182-183,共2页Journal of Jining Medical University

摘　　要：目的研究血管活性物质尾加压素Ⅱ(UⅡ)、血管紧张素Ⅱ(AngⅡ)和内皮素-1(ET-1)在冠心病患者体内的变化,以探讨它们在冠心病发病过程中的意义。方法采用放射免疫法测定44例冠心病患者和30例健康体检者的血浆UⅡ、AngⅡ和ET-1的变化。结果冠心病患者血浆UⅡ、AngⅡ和ET-1的含量分别是1.51±0.44pg/ml,114.14±15.91pg/ml,98.64±9.58pg/ml;健康对照组血浆UⅡ、AngⅡ和ET-1的含量分别是4.41±0.57pg/ml,66.65±12.22pg/ml,49.16±6.69pg/ml;两组比较,差异有显著性(P<0.01)。结论UⅡ、AngⅡ和ET-1可能对冠心病的发生发展有促进作用,可做为临床观察病情发展的重要指标。Objective To investigate changes of plasma urotensin Ⅱ,angiotensin Ⅱ and endothelin-1 levels in patients with coronary heart disease,and to explore the pathophysiological roles of U Ⅱ ,Ang Ⅱ and ET-1 in this diseases. Methods The plasma U Ⅱ,Ang Ⅱ and ET-1 in 44 patients with coronary heart disease and 30 normal cases were detected by radioimmunoassay. Results The plasma UⅡ ,Ang Ⅱ and ET-1 levels of test group were 1.51±0.44pg/ml, 114.14 ± 15.91pg/m1.98.64±9.58pg/ml separately. Those of control group were 4. 41 ± 0.57pg/ml,66.65 ± 12.22pg/ml,49.16±6.69pg/ml. There were significant differences between 2 groups（P〈0.01）. Conclusion U Ⅱ,Ang Ⅱ and ET-1 could contribute to the development of coronary heart disease, they could be regarded clinical target of coronary heart disease developing.

关 键 词：冠心病 尾加压素Ⅱ 血管紧张素Ⅱ 内皮素-1 

分 类 号：R541.4[医药卫生—心血管疾病]